S
Sverre E. Kjeldsen
Researcher at University of Oslo
Publications - 771
Citations - 95426
Sverre E. Kjeldsen is an academic researcher from University of Oslo. The author has contributed to research in topics: Blood pressure & Left ventricular hypertrophy. The author has an hindex of 94, co-authored 735 publications receiving 89059 citations. Previous affiliations of Sverre E. Kjeldsen include University of Michigan & Cornell University.
Papers
More filters
Journal ArticleDOI
Critical aspects in hypertension diagnosis and treatment.
TL;DR: Previously, the reliability of patient self-assessed blood pressures was questioned based on poor accuracy and reproducibility of the available automated blood pressure monitoring devices, but modern technology has largely solved such problems, as demonstrated by Germano and coworkers in their assessment of four automatic devices for selfmeasurement of blood pressure.
Journal ArticleDOI
In memoriam: Peter Sleight 1929-2020.
Reinhold Kreutz,Sverre E. Kjeldsen,Michel Burnier,Krzysztof Narkiewicz,Suzanne Oparil,Giuseppe Mancia +5 more
TL;DR: The sad news came to us of Peter Sleight's passing on 7 October 2020 and a note reached us from Christopher Sleight, Peter’s oldest son: ‘My sad news is tha...
Institutional report - Coronary Echocardiographic demonstration of improved myocardial function early after coronary artery bypass graft surgery
Camilla Lund Søraas,Anne Cecilie,K. Larstorp,Arild Mangschau,Sverre E. Kjeldsen,Reidar Bjørnerheim +5 more
TL;DR: The data suggest that CABG improves myocardial contractility within the first days postoperatively, and echocardiographic determination of wall motion is a useful tool to observe LV function.
Journal ArticleDOI
Direct renin inhibitors in hypertension - approaching the moment of truth.
TL;DR: The potential risks of cardiovascular and renal adverse events in patients with type 2 diabetes and renal impairment and/or cardiovascular disease treated with aliskiren (Tekturna ® ) tablets andAliskiren-containing combination products are discussed.
Journal ArticleDOI
Does GISSI-AF change the concept of using RAS inhibitors in the primary prevention of atrial fibrillation in hypertensive patients?
TL;DR: ARBs appear to be effective in the primary prevention of AF, at least in hypertensive patients, and results of the large ONTARGET Trial suggest that ARBs and ACEIs are probably equally effective in preventing AF in a high-risk population.